From BIOD Website
Biodel Announces Completion of Dosing in Phase 2 Clinical Trial of BIOD-123 in Patients With Type 1 Diabetes
Top-Line Data Expected in Third Quarter of 2013
DANBURY, Conn. (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that all scheduled follow-up visits have been completed for patients enrolled in the Phase 2 clinical trial of BIOD-123, an investigational ultra-rapid-acting injectable mealtime insulin therapy.
Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "Completing the BIOD-123 Phase 2 clinical trial is another significant milestone in the development of novel ultra-rapid-acting meal time insulins to aid patients and healthcare professionals in the treatment of diabetes. We look forward to sharing the top-line results by the end of this quarter."